Business Context and Reporting Period
Company: American Shared Hospital Services (ASHS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2005
Business Overview: ASHS provides Gamma Knife stereotactic radiosurgery services to 21 medical centers across 18 U.S. states. The company operates through GK Financing, LLC (GKF), in which ASHS holds an 81% interest and Elekta AG (the equipment manufacturer) holds 19%. Gamma Knife services accounted for 100% of revenue in 2005. The company is developing a new product, "OR21," but it is not expected to generate significant revenue within the next 12 months.
Key Financial Metrics (Year Ended Dec 31, 2005)
| Metric | 2005 | 2004 |
|---|---|---|
| Medical Services Revenue | $18,231,000 | $16,389,000 |
| Net Income | $1,767,000 | $1,985,000 |
| Diluted EPS | $0.35 | $0.39 |
| Operating Cash Flow | $8,480,000 | $7,608,000 |
| Long-Term Debt & Capital Leases | $25,082,000 | $25,486,000 |
| Cash & Cash Equivalents | $1,298,000 | $8,121,000 |
| Working Capital | $2,423,000 | $4,978,000 |
| Gross Margin | 50.2% | 51.9% |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 11.2% to $18.2 million, driven by the addition of three new Gamma Knife units in 2005 and the full-year inclusion of a unit added in 2004. This offset a 4% revenue decline from older units.
- Net Income Decline: Net income decreased 11.0% to $1.77 million. While operating income increased by $193,000 due to new units, income tax expense rose significantly ($368,000 increase) due to reduced tax benefits from stock option exercises compared to 2004.
- Liquidity Shift: Cash and cash equivalents dropped from $8.1 million to $1.3 million. This was primarily due to a strategic decision to invest $6.4 million of available cash into marketable securities (current and long-term) to maximize income.
- Cost Increases: Costs of operations rose 15.0% to $9.1 million, largely due to increased depreciation from new units and the expiration of warranties on older equipment. Selling and administrative expenses increased 21.9% due to payroll, business development, and legal fees.
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management anticipates declaring and paying quarterly cash dividends in similar amounts to 2005, subject to earnings and cash availability. The company expects to continue financing Gamma Knife units with debt.
- Reimbursement Risk: A significant risk is the potential decline in federal reimbursement rates (Medicare/Medicaid). However, the filing notes a scheduled 28% increase in Medicare outpatient reimbursement rates effective January 1, 2006, which should benefit four specific contracts.
- Debt and Financing: The company carries a high level of debt ($25.1 million), collateralized by Gamma Knife units. While the primary lender (DVI) filed for bankruptcy in 2003, loans were assumed by a successor servicer, and the company remains in compliance with all covenants.
- Technology Obsolescence: The company faces risks regarding new technology (e.g., Elekta's Model 4C upgrade). Upgrading existing units is estimated to cost between $200,000 and $1,000,000 per unit.
- Regulatory: The company is subject to federal anti-kickback statutes, Stark II laws, and Certificate of Need (CON) requirements in various states.
Investor Verification Checklist
- Debt Covenants: Verify continued compliance with debt covenants given the high leverage ratio and reliance on third-party lenders.
- Reimbursement Rates: Monitor the actual impact of the 28% Medicare outpatient rate increase in 2006 on the six revenue-sharing contracts.
- Capital Expenditures: Assess the timing and cost of required upgrades to existing Gamma Knife units to prevent technological obsolescence.
- Customer Concentration: Confirm that no single customer exceeds 10% of revenue (currently true) and monitor the stability of the 21 existing contracts.
- Liquidity Management: Review the strategy for holding significant assets in marketable securities versus cash to ensure sufficient liquidity for debt service and dividends.